Although the von Willebrand disease is relatively rare, it is one of the most common bleeding disorders. Diagnosis and von Willebrand diseases treatment around the world continue to vary due to which, several key players operating in the current von Willebrand disease treatment market landscape are increasingly seeking opportunities to collaborate with other players involved, and redefine current norms and guidelines pertaining to the von Willebrand diseases treatment. Several major government and private sector organizations are forging strategic alliances to increase efficacy and success rate of existing and upcoming treatments.
Clinical guidelines laid down by the World Federation of Hemophilia (WFH) are recognized worldwide and implemented by healthcare providers. Although the guidelines issued by the WFH are largely relied upon, efforts are being made to maintain state-of-the-art guidelines for von Willebrand disease. Research and development activities are expected to play a major role in boosting the overall prospects of the global von Willebrand disease treatment market during the forecast period, and also pave the path for new therapies and diagnostics framework. Players operating in the current von Willebrand disease treatment market are projected to focus on drug development, refine existing therapies, and gain approval from the FDA for their advancements.
At the back of these factors, the global von Willebrand disease treatment market is expected to attain a market value of ~US$ 900 Mn by the end of 2030. In addition, increasing support from governments, rise in government initiatives, and surge in demand for recombinant therapies are factors that are likely to aid the growth of the market for von Willebrand disease treatment during the assessment period.
While research and development activities are likely to gain considerable momentum in the upcoming years, collaborations between regulatory bodies around the world are projected to witness considerable growth as efforts are in full swing to standardize the diagnostics and von Willebrand disease treatment worldwide. Collaborations and joint ventures are also on the rise, particularly to streamline drug development and curate clinical guidelines. For instance, the American Society of Hematology (ASH), the National Hemophilia Foundation (NHF), and the International Society on Thrombosis and Haemostasis (ISTH) entered a collaboration with each other to develop clinical guidelines due to the glaring differences in diagnosis and treatment practices of von Willebrand disease worldwide. As such, collaborations continue to rise across the von Willebrand disease treatment market, the quality and efficacy of von Willebrand disease treatment is likely to grow in the forthcoming decade– a major factor that is expected to accelerate the growth of the von Willebrand disease treatment market.
Research and development activities are set to play an important role in augmenting the growth of the global von Willebrand disease treatment market during the assessment period. The entry of new therapies and von Willebrand disease treatment, as a result of research programs and initiatives, is expected to provide a considerable boost to the global von Willebrand disease treatment market. Majorly, the management of von Willebrand disease is mainly based on the dual correction of primary hemostasis defect caused due to inherited deficiency of von Willebrand factor (VWF) and the secondary defect factor VIII coagulant activity. At present, new therapies are aimed toward addressing primary deficiency in the von Willebrand disease. Considerable research is being carried out to evaluate the efficacy of new products in different clinical situations. In addition, scientists and researchers are also focusing on testing the efficacy of new therapies and products in unexplored situations, including long-term use of prophylaxis, use in children, and during recurrent gastrointestinal bleeding.
The ongoing COVID-19 pandemic is expected to have a short-term impact on the overall growth of the global von Willebrand disease treatment market. Although the sales of medication and adoption of various therapies could see a slight dip due to the COVID-19 situation, research and development activities are expected to continue in full swing across the von Willebrand disease treatment market. Several research institutes around the world are increasingly assessing the relationship between von Willebrand disease and COVID-19 due to which, new areas pertaining to von Willebrand disease treatment are being explored. While drug development and research activities are likely to remain unaffected, the number of clinical tests and procedures could potentially witness a slight dip in 2020.
Analysts’ Viewpoint
The global von Willebrand disease treatment market is expected to expand at a healthy CAGR of ~6% during the forecast period. The market growth is largely driven by factors, including increasing collaborations and partnerships between top-tier research institutes and regulatory bodies, entry of new von Willebrand disease therapies, and growing awareness related to von Willebrand disease due to a surge in the number of government initiatives and awareness programs. While research and development activities are set to play an imperative role in the expansion of the von Willebrand disease treatment market, other factors that are likely to influence the market growth include rise in demand for recombinant therapies and strong product pipeline.
Von Willebrand Disease Treatment Market – Segmentation
TMR’s study on the global von Willebrand disease treatment market includes information divided into six segments: disease type, drug, gender, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global von Willebrand disease treatment market have been discussed in detail.
|
Disease Type |
|
|
Drug |
|
|
Route of Administration |
|
|
Gender |
|
|
Distribution Channel |
|
|
Region |
|
von willebrand disease treatment market is expected to attain a market value of ~US$ 900 Mn by the end of 2030
von Willebrand disease treatment market is expected to expand at a healthy CAGR of ~6% during 2020 - 2030
von Willebrand disease treatment market is driven by rise in government initiatives and surge in demand for recombinant therapies
North America accounted for a major share of the global von Willebrand disease treatment market and this trend is anticipated to continue during the forecast period
Key players operating in the global von Willebrand disease treatment market include Octapharma AG, Grifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., and Ferring B.V.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Von Willebrand Disease Treatment Market Forecast
4.5. Global Von Willebrand Disease Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence Rate Globally with Key Countries
5.3. Key Industrial Events(Licensing Partnership/Merger & Acquisition)
5.4. Average Annual Cost of Therapy
5.5. Reimbursement Scenario - Global Von Willebrand Disease
5.6. Disease Overview
5.7. Regulatory Scenario, by Region/globally
5.8. Treatment Options For Women with Menorrhagia in Von Willebrand Disease
5.9. Covid-19 Impact Analysis
6. Global Von Willebrand Disease Treatment Market Analysis, by Disease Type
6.1. Introduction
6.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
6.3. Global Von Willebrand Disease Treatment Market Forecast, by Disease Type
6.3.1. Type 1 Von Willebrand Disease
6.3.2. Type 2 Von Willebrand Disease
6.3.3. Type 3 Von Willebrand Disease
6.3.4. Acquired Von Willebrand Disease
6.4. Global Von Willebrand Disease Treatment Market Analysis, by Disease Type
7. Global Von Willebrand Disease Treatment Market Analysis, by Drug
7.1. Introduction
7.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
7.3. Global Von Willebrand Disease Treatment Market Forecast, by Drug
7.3.1. Desmopressin
7.3.2. Clot-stabilizing medications
7.3.3. Replacement therapies
7.3.4. Contraceptives
7.3.5. Others
7.4. Global Von Willebrand Disease Treatment Market Analysis, by Drug
8. Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration
8.1. Introduction
8.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
8.3. Global Von Willebrand Disease Treatment Market Forecast, by Route of Administration
8.3.1. Oral
8.3.2. Injection
8.3.3. Other
8.4. Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration
9. Global Von Willebrand Disease Treatment Market Analysis, by Gender
9.1. Introduction
9.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
9.3. Global Von Willebrand Disease Treatment Market Forecast, by Gender
9.3.1. Men
9.3.2. Women
9.4. Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration
10. Global Von Willebrand Disease Treatment Market Analysis, by Distribution Channel
10.1. Introduction
10.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.3. Global Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Global Von Willebrand Disease Treatment Market Analysis, by Distribution Channel
11. Global Von Willebrand Disease Treatment Market Analysis, by Region
11.1. Global Von Willebrand Disease Treatment Market Scenario, by Region/Country
11.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Region
11.3. Global Von Willebrand Disease Treatment Market Forecast, by Region
11.3.1. North America
11.3.2. Europe
11.3.3. Asia Pacific
11.3.4. Latin America
11.3.5. Middle East & Africa
12. North America Von Willebrand Disease Treatment Market Analysis
12.1. Key Findings
12.2. North America Von Willebrand Disease Treatment Market Overview
12.3. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country
12.4. North America Von Willebrand Disease Treatment Market Forecast, by Country
12.4.1. U.S.
12.4.2. Canada
12.5. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
12.6. North America Von Willebrand Disease Treatment Market Forecast, by Disease Type
12.6.1. Type 1 Von Willebrand Disease
12.6.2. Type 2 Von Willebrand Disease
12.6.3. Type 3 Von Willebrand Disease
12.6.4. Acquired Von Willebrand Disease
12.7. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
12.8. North America Von Willebrand Disease Treatment Market Forecast, by Drug
12.8.1. Desmopressin
12.8.2. Clot-stabilizing medications
12.8.3. Replacement therapies
12.8.4. Contraceptives
12.8.5. Others
12.9. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
12.10. North America Von Willebrand Disease Treatment Market Forecast, by Route of Administration
12.10.1. Oral
12.10.2. Injection
12.10.3. Others
12.11. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
12.12. North America Von Willebrand Disease Treatment Market Forecast, by Gender
12.12.1. Men
12.12.2. Women
12.13. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.14. North America Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
12.14.1. Hospital pharmacies
12.14.2. Retail pharmacies
12.14.3. Online pharmacies
13. Europe Von Willebrand Disease Treatment Market Analysis
13.1. Key Findings
13.2. Europe Von Willebrand Disease Treatment Market Overview
13.3. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Europe Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region
13.4.1. Germany
13.4.2. France
13.4.3. U.K.
13.4.4. Italy
13.4.5. Spain
13.4.6. Rest of Europe
13.5. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
13.6. Europe Von Willebrand Disease Treatment Market Forecast, by Disease Type
13.6.1. Type 1 Von Willebrand Disease
13.6.2. Type 2 Von Willebrand Disease
13.6.3. Type 3 Von Willebrand Disease
13.6.4. Acquired Von Willebrand Disease
13.7. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
13.8. Europe Von Willebrand Disease Treatment Market Forecast, by Drug
13.8.1. Desmopressin
13.8.2. Clot-stabilizing medications
13.8.3. Replacement therapies
13.8.4. Contraceptives
13.8.5. Others
13.9. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
13.10. Europe Von Willebrand Disease Treatment Market Forecast, by Route of Administration
13.10.1. Oral
13.10.2. Injection
13.10.3. Others
13.11. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
13.12. Europe Von Willebrand Disease Treatment Market Forecast, by Gender
13.12.1. Men
13.12.2. Women
13.13. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.14. Europe Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
13.14.1. Hospital pharmacies
13.14.2. Retail pharmacies
13.14.3. Online pharmacies
14. Asia Pacific Von Willebrand Disease Treatment Market Analysis
14.1. Key Findings
14.2. Asia Pacific Von Willebrand Disease Treatment Market Overview
14.3. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region
14.4.1.1. Japan
14.4.1.2. China
14.4.1.3. India
14.4.2. Australia & New Zealand
14.4.3. Rest of Asia Pacific
14.5. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
14.6. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Disease Type
14.6.1. Type 1 Von Willebrand Disease
14.6.2. Type 2 Von Willebrand Disease
14.6.3. Type 3 Von Willebrand Disease
14.6.4. Acquired Von Willebrand Disease
14.7. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
14.8. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Drug
14.8.1. Desmopressin
14.8.2. Clot-stabilizing medications
14.8.3. Replacement therapies
14.8.4. Contraceptives
14.8.5. Others
14.9. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
14.10. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Route of Administration
14.10.1. Oral
14.10.2. Injection
14.10.3. Others
14.11. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
14.12. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Gender
14.12.1. Men
14.12.2. Women
14.13. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.14. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
14.14.1. Hospital pharmacies
14.14.2. Retail pharmacies
14.14.3. Online pharmacies
15. Latin America Von Willebrand Disease Treatment Market Analysis
15.1. Key Findings
15.2. Latin America Von Willebrand Disease Treatment Market Overview
15.3. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country
15.4. Latin America Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region
15.4.1. Brazil
15.4.2. Mexico
15.4.3. Rest of Latin America
15.5. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
15.6. Latin America Von Willebrand Disease Treatment Market Forecast, by Disease Type
15.6.1. Type 1 Von Willebrand Disease
15.6.2. Type 2 Von Willebrand Disease
15.6.3. Type 3 Von Willebrand Disease
15.6.4. Acquired Von Willebrand Disease
15.7. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
15.8. Latin America Von Willebrand Disease Treatment Market Forecast, by Drug
15.8.1. Desmopressin
15.8.2. Clot-stabilizing medications
15.8.3. Replacement therapies
15.8.4. Contraceptives
15.8.5. Others
15.9. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
15.10. Latin America Von Willebrand Disease Treatment Market Forecast, by Route of Administration
15.10.1. Oral
15.10.2. Injection
15.10.3. Others
15.11. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
15.12. Latin America Von Willebrand Disease Treatment Market Forecast, by Gender
15.12.1. Men
15.12.2. Women
15.13. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
15.14. Latin America Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
15.14.1. Hospital pharmacies
15.14.2. Retail pharmacies
15.14.3. Online pharmacies
16. Middle East & Africa Von Willebrand Disease Treatment Market Analysis
16.1. Key Findings
16.2. Middle East & Africa Von Willebrand Disease Treatment Market Overview
16.3. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country
16.4. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region
16.4.1. GCC Countries
16.4.2. South Africa
16.4.3. Rest of Middle East & Africa
16.5. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type
16.6. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Disease Type
16.6.1. Type 1 Von Willebrand Disease
16.6.2. Type 2 Von Willebrand Disease
16.6.3. Type 3 Von Willebrand Disease
16.6.4. Acquired Von Willebrand Disease
16.7. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug
16.8. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Drug
16.8.1. Desmopressin
16.8.2. Clot-stabilizing medications
16.8.3. Replacement therapies
16.8.4. Contraceptives
16.8.5. Others
16.9. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration
16.10. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Route of Administration
16.10.1. Oral
16.10.2. Injection
16.10.3. Others
16.11. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender
16.12. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Gender
16.12.1. Men
16.12.2. Women
16.13. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
16.14. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Distribution Channel
16.14.1. Hospital pharmacies
16.14.2. Retail pharmacies
16.14.3. Online pharmacies
17. Competitive Landscape
17.1. Company Profile
17.1.1. Octapharma AG
17.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.1.2. Financial Overview
17.1.1.3. Product Portfolio
17.1.1.4. SWOT Analysis
17.1.1.5. Strategic Overview
17.1.2. Grifols, S.A.
17.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.2.2. Financial Overview
17.1.2.3. Product Portfolio
17.1.2.4. SWOT Analysis
17.1.2.5. Strategic Overview
17.1.3. Shire Plc.
17.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.3.2. Financial Overview
17.1.3.3. Product Portfolio
17.1.3.4. SWOT Analysis
17.1.3.5. Strategic Overview
17.1.4. Bayer AG
17.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.4.2. Product Portfolio
17.1.4.3. SWOT Analysis
17.1.4.4. Strategic Overview
17.1.5. CSL Limited
17.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.5.2. Financial Overview
17.1.5.3. Product Portfolio
17.1.5.4. SWOT Analysis
17.1.5.5. Strategic Overview
17.1.6. Pfizer, Inc
17.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.6.2. Financial Overview
17.1.6.3. Product Portfolio
17.1.6.4. SWOT Analysis
17.1.6.5. Strategic Overview
17.1.7. Akorn, Inc.
17.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.7.2. Financial Overview
17.1.7.3. Product Portfolio
17.1.7.4. SWOT Analysis
17.1.7.5. Strategic Overview
17.1.8. Ferring B.V.
17.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.1.8.2. Financial Overview
17.1.8.3. Product Portfolio
17.1.8.4. SWOT Analysis
17.1.8.5. Strategic Overview
List of Tables
Table 01: Key Mergers & Acquisition in the Von Willebrand Disease Treatment Market
Table 02: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 03: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 04: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 05: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 06: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 07: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 08: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 09: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 10: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 11: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 12: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 13: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 14: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 15: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 16: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 17: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 18: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 19: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 20: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 21: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 22: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 23: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 24: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 25: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 26: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 27: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 28: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 29: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 30: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 31: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 32: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 33: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 34: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030
Table 35: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 36: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030
Table 37: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Von Willebrand Disease Treatment Market Value Share, by Disease Type, 2019
Figure 03: Global Von Willebrand Disease Treatment Market Value Share, by Drug, 2019
Figure 04: Global Von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2019
Figure 05: Global Von Willebrand Disease Treatment Market Value Share, by Gender, 2019
Figure 06: Global Von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2019
Figure 07: Global Von Willebrand Disease Treatment Market Value Share, by Region, 2019
Figure 08: Regulatory Approval Process - U.S.
Figure 09: Regulatory Approval Process - Europe
Figure 10: Regulatory Approval Process - Japan
Figure 11: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 12: Global Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 13: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 1 Von Willebrand Disease, 2018–2030
Figure 14: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 2 Von Willebrand Disease, 2018–2030
Figure 15: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 3 Von Willebrand Disease, 2018–2030
Figure 16: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Acquired Von Willebrand Disease, 2018–2030
Figure 17: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 18: Global Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 19: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Desmopressin, 2018–2030
Figure 20: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Clot-stabilizing Medications, 2018–2030
Figure 21: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Replacement therapies, 2018–2030
Figure 22: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Contraceptives, 2018–2030
Figure 23: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Others, 2018–2030
Figure 24: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 25: Global Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 26: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Oral, 2018–2030
Figure 27: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Injection, 2018–2030
Figure 28: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Others, 2018–2030
Figure 29: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 30: Global Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
List of Figure
Figure 31: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Men, 2018–2030
Figure 32: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Injection, 2018–2030
Figure 33: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 34: Global Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 35: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2018–2030
Figure 36: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2018–2030
Figure 37: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Online Pharmacies, 2018–2030
Figure 38: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 39: Global Von Willebrand Disease Treatment Market Attractiveness Analysis, by Region
Figure 40: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 41: North America Von Willebrand Disease Treatment Market Value Share (%), by Country, 2019 and 2030
Figure 42: North America Von Willebrand Disease Treatment Market Attractiveness, by Country, 2020–2030
Figure 43: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 44: North America Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 45: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 46: North America Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 47: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 48: North America Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 49: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 50: North America Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
Figure 51: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 52: North America Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 53: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 54: Europe Von Willebrand Disease Treatment Market Value Share (%), by Countries/Sub-region, 2019 and 2030
Figure 55: Europe Von Willebrand Disease Treatment Market Attractiveness, by Countries/Sub-region, 2020–2030
Figure 56: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 57: Europe Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 58: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 59: Europe Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 60: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 61: Europe Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 62: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 63: Europe Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
Figure 64: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 65: Europe Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 66: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 67: Asia Pacific Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 68: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 69: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 70: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 71: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 72: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 73: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 74: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 75: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 76: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
Figure 77: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 78: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 79: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 80: Latin America Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 81: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 82: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 83: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 84: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 85: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 86: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 87: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 88: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 89: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
Figure 90: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 91: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 92: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 93: Middle East & Africa Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 94: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 95: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 96: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030
Figure 97: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030
Figure 98: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030
Figure 99: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 100: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 101: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030
Figure 102: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030
Figure 103: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 104: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Von Willebrand Disease Treatment Market
